Rat Angiotensinogen (AGT) CLIA Kit

Product specifications

CLIA Kits

Angiotensinogen (AGT)

Rat

Chemiluminescent

Quantitative

Sandwich

0.781 ng/ml - 50 ng/ml

< 0.34 ng/ml

Optimal dilutions/concentrations should be determined by the end user.

96 tests

5 × 96 tests

10 × 96 tests

Lyophilized

CLIA

Serum, plasma, tissue homogenates and other biological fluids.

Shipped within 5-20 working days.

 Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

No

ANHU,SERPINA8,hFLT1

CLIA Kits AGT

RUO

The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request.   This product is for research use only.   The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments.   Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Descripción

Angiotensinogen (AGT) is a protein primarily produced and secreted by the liver, although it is also synthesized by other tissues, including the kidney and adipose tissue. It serves as the precursor molecule for the renin-angiotensin system (RAS), a key regulatory pathway involved in blood pressure regulation, fluid balance, and electrolyte homeostasis. AGT is converted into angiotensin I by the enzyme renin, which is released by the kidneys in response to various stimuli, such as decreased blood pressure or sodium levels. Angiotensin I is further converted into angiotensin II by angiotensin-converting enzyme (ACE), leading to vasoconstriction, aldosterone release, and sodium reabsorption, ultimately raising blood pressure. Dysregulation of the RAS, including alterations in AGT levels, has been implicated in hypertension, cardiovascular disease, and kidney disorders. Therapeutic interventions targeting the RAS, such as ACE inhibitors and angiotensin receptor blockers, are commonly used to manage hypertension and related conditions. Understanding the role of AGT in the RAS provides insights into cardiovascular health and potential avenues for therapeutic intervention. Ongoing research continues to elucidate the intricate mechanisms underlying AGT regulation and its implications for human health and disease

Related Products

Human AGT(Angiotensinogen) ELISA Kit

Ver Producto

Mouse Agt(Angiotensinogen) ELISA Kit

Ver Producto

Porcine AGT(Angiotensinogen ) ELISA Kit

Ver Producto